Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or ...

Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Average weight dropped from 98.1 kg (216.3 lb) to 86.7 kg (191.1 ... to primary endpoint in other SURPASS phase III studies," they said. Both the tirzepatide and dulaglutide groups had reductions ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

For patients with inadequately controlled T2D receiving dulaglutide, switching to tirzepatide is associated with additional HbA1c reduction and weight loss.

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Researchers have found in a new research that among patients with poorly controlled type 2 diabetes, switching from ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

(RTTNews) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The company ...

The change from baseline in weight at week 40 was −10.5 and −3.6 kg with tirzepatide and dulaglutide, respectively. Overall, 7.2 and 7.0% of tirzepatide- and dulaglutide-treated patients ...